Pulmonary Arterial Hypertension (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension – Drugs In Development, 2021, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 10, 12, 19, 1, 45, 11 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 8 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Aadi Bioscience Inc

Abivax SA

Acceleron Pharma Inc

Advent Therapeutics Inc

Aeon Respire Inc

Aerami Therapeutics Inc

Aerogen Ltd

Aerovate Therapeutics Inc

AI Therapeutics Inc

Algorithm Sciences Inc

Altavant Sciences Inc

Alterras Therapeutics GmbH

Apaxen

APEIRON Biologics AG

Apollo Therapeutics LLC

APT Therapeutics Inc

Aqualung Therapeutics Corp

AstraZeneca Plc

ATXA Therapeutics Ltd

Bayer AG

Bial – Portela & Ca SA

Biogen Inc

Biozeus Pharmaceutical SA

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

C4X Discovery Holdings Plc

Camurus AB

Capricor Therapeutics Inc

Celon Pharma SA

Celsion Corp

Celtaxsys Inc

Centessa Pharmaceuticals Plc

Cereno Scientific AB

Chiesi Farmaceutici SpA

Corsair Pharma Inc

Denovo Biopharma LLC

Eli Lilly and Co

Excubio Pharmaceuticals Inc

Galectin Therapeutics Inc

GenThera Inc

GEXVal Inc

Gilead Sciences Inc

Gmax Biopharm LLC

Gossamer Bio Inc

Hanmi Pharmaceuticals Co Ltd

Insmed Inc

Interprotein Corp

INVENT Pharmaceuticals Inc

Johnson & Johnson

Keros Therapeutics Inc

Liquidia Technologies Inc

LTT Bio-Pharma Co Ltd

Martin Pharmaceuticals Inc

Merck & Co Inc

Mifcare

Nadian Bio Ltd

Nippon Shinyaku Co Ltd

Nissan Chemical Corp

Northern Therapeutics Inc

Novartis AG

Pfizer Inc

Pharmosa Biopharm Inc

PhaseBio Pharmaceuticals Inc

Proteo Inc

PulmoSIM Therapeutics

Q BioMed Inc

Radikal Therapeutics Inc

Recursion Pharmaceuticals Inc

Respira Therapeutics Inc

Resverlogix Corp

Reviva Pharmaceuticals Inc

Ribomic Inc

Shijiazhuang Sagacity New Drug Development Co Ltd

SteadyMed Therapeutics Inc

Suda Pharmaceuticals Ltd

Sulfateq BV

Systimmune Inc

Tenax Therapeutics Inc

Topadur Pharma AG

Translate Bio Inc

Triastek Inc

Tritech Biopharmaceuticals Co Ltd

United Therapeutics Corp

Vascular BioSciences

Vasculonics LLC

VasThera Co Ltd

Vivus Inc

Table of Contents

Table of Contents

Introduction

Pulmonary Arterial Hypertension - Overview

Pulmonary Arterial Hypertension - Therapeutics Development

Pulmonary Arterial Hypertension - Therapeutics Assessment

Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development

Pulmonary Arterial Hypertension - Drug Profiles

Pulmonary Arterial Hypertension - Dormant Projects

Pulmonary Arterial Hypertension - Discontinued Products

Pulmonary Arterial Hypertension - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pulmonary Arterial Hypertension – Pipeline by Aadi Bioscience Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Abivax SA, 2021

Pulmonary Arterial Hypertension – Pipeline by Acceleron Pharma Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Advent Therapeutics Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Aeon Respire Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Aerami Therapeutics Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Aerogen Ltd, 2021

Pulmonary Arterial Hypertension – Pipeline by Aerovate Therapeutics Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by AI Therapeutics Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Algorithm Sciences Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Altavant Sciences Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Alterras Therapeutics GmbH, 2021

Pulmonary Arterial Hypertension – Pipeline by Apaxen, 2021

Pulmonary Arterial Hypertension – Pipeline by APEIRON Biologics AG, 2021

Pulmonary Arterial Hypertension – Pipeline by Apollo Therapeutics LLC, 2021

Pulmonary Arterial Hypertension – Pipeline by APT Therapeutics Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Aqualung Therapeutics Corp, 2021

Pulmonary Arterial Hypertension – Pipeline by AstraZeneca Plc, 2021

Pulmonary Arterial Hypertension – Pipeline by ATXA Therapeutics Ltd, 2021

Pulmonary Arterial Hypertension – Pipeline by Bayer AG, 2021

Pulmonary Arterial Hypertension – Pipeline by Bial – Portela & Ca SA, 2021

Pulmonary Arterial Hypertension – Pipeline by Biogen Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Biozeus Pharmaceutical SA, 2021

Pulmonary Arterial Hypertension – Pipeline by Boehringer Ingelheim International GmbH, 2021

Pulmonary Arterial Hypertension – Pipeline by Bristol-Myers Squibb Co, 2021

Pulmonary Arterial Hypertension – Pipeline by C4X Discovery Holdings Plc, 2021

Pulmonary Arterial Hypertension – Pipeline by Camurus AB, 2021

Pulmonary Arterial Hypertension – Pipeline by Capricor Therapeutics Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Celon Pharma SA, 2021

Pulmonary Arterial Hypertension – Pipeline by Celsion Corp, 2021

Pulmonary Arterial Hypertension – Pipeline by Celtaxsys Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Centessa Pharmaceuticals Plc, 2021

Pulmonary Arterial Hypertension – Pipeline by Cereno Scientific AB, 2021

Pulmonary Arterial Hypertension – Pipeline by Chiesi Farmaceutici SpA, 2021

Pulmonary Arterial Hypertension – Pipeline by Corsair Pharma Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Denovo Biopharma LLC, 2021

Pulmonary Arterial Hypertension – Pipeline by Eli Lilly and Co, 2021

Pulmonary Arterial Hypertension – Pipeline by Excubio Pharmaceuticals Inc, 2021

Pulmonary Arterial Hypertension – Pipeline by Galectin Therapeutics Inc, 2021

Pulmonary Arterial Hypertension – Dormant Projects, 2021

Pulmonary Arterial Hypertension – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports